Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Fibril-associated Collagen01:11

Fibril-associated Collagen

3.2K
Fibril-associated collagens are a type of collagens present in the extracellular matrix with interrupted triple helices or FACIT (Fibril-associated collagens interrupted triple-helices). FACIT help connect and attach the collagen fibrils with each other as well as with other proteins of the extracellular matrix.
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
3.2K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.5K
Protein Complexes with Interchangeable Parts01:57

Protein Complexes with Interchangeable Parts

2.8K
Groups of proteins may form a complex where each protein in this complex has a different role in the overall execution of the complex’s function. Often some of the proteins in the complex can be replaced by a closely related variant to give a complex that contains many of the same components yet is functionally distinct.
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
2.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Protein Complex Assembly02:41

Protein Complex Assembly

16.5K
Proteins can form homomeric complexes with another unit of the same protein or heteromeric complexes with different types.  Most protein complexes self-assemble spontaneously via ordered pathways, while some proteins need assembly factors that guide their proper assembly. Despite the crowded intracellular environment, proteins usually interact with their correct partners and form functional complexes.
Many viruses self-assemble into a fully functional unit using the infected host cell to...
16.5K
Fibronectins Connect Cells with ECM01:25

Fibronectins Connect Cells with ECM

3.2K
Fibronectin is an adhesive glycoprotein present in the extracellular matrix of embryogenic and adult tissue. These molecules primarily aid in regulating cell motility and attachment. A fibronectin molecule is composed of two identical polypeptide chains attached to each other by a pair of disulfide bonds at the C-terminal.
Both proteoglycans and collagen are attached to fibronectin proteins, which, in turn, are attached to integrin proteins. These integrin proteins interact with transmembrane...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Poor Mobilization and Plerixafor Use in Matched Related Peripheral Hematopoietic Progenitor Cell Donors.

Journal of clinical apheresis·2025
Same author

Analysis of 52 240 source plasma donors of convalescent COVID-19 plasma: Sex, ethnicity, and age association with initial antibody levels and rate of dissipation.

Journal of clinical apheresis·2022
Same author

Source plasma deferral trends: A 3-year analysis of 255 centers in the United States.

Journal of clinical apheresis·2021
Same author

Structure of human factor VIIa-soluble tissue factor with calcium, magnesium and rubidium.

Acta crystallographica. Section D, Structural biology·2021
Same author

Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1.

Journal of clinical medicine·2020
Same author

Plasmin-mediated proteolysis of human factor IXa in the presence of calcium/phospholipid: Conversion of procoagulant factor IXa to a fibrinolytic enhancer.

Journal of thrombosis and haemostasis : JTH·2020

Related Experiment Videos

Structure-function relationships in factor IX and factor IXa.

Amy E Schmidt1, S Paul Bajaj

  • 1Departments of Pharmacological & Physiological Sciences and Internal Medicine, Saint Louis University Health Sciences Center, MO 63110, USA.

Trends in Cardiovascular Medicine
|January 30, 2003
PubMed
Summary
This summary is machine-generated.

This study explores Factor IX (FIX) interactions in blood coagulation. Targeting FIX binding sites could lead to new antithrombotic therapies.

Related Experiment Videos

Area of Science:

  • Biochemistry
  • Hematology
  • Molecular Biology

Background:

  • Factor IX (FIX) is a critical protein in the blood coagulation cascade.
  • FIX possesses distinct domains: gamma-carboxyglutamic acid (Gla), two epidermal growth factor-like (EGF) domains, and a serine protease domain.
  • FIX activation is primarily mediated by the FVIIa/tissue factor (TF) complex.

Purpose of the Study:

  • To elucidate the specific domains of FIX involved in its activation by FVIIa/TF.
  • To understand the molecular interactions between activated FIX (FIXa) and FVIIIa during FX activation.
  • To identify potential pharmacologic targets within these interactions for developing novel antithrombotic agents.

Main Methods:

  • The study likely involves biochemical assays and structural analyses to investigate protein-protein interactions.
  • Computational modeling may be used to predict binding interfaces.
  • Functional assays would assess the impact of disrupting specific interactions on coagulation activity.

Main Results:

  • The Gla and EGF1 domains of FIX are implicated in the interaction with TF.
  • The protease domain and potentially the EGF2 domain of FIXa are crucial for specific binding to FVIIIa.
  • These interactions are essential for the efficient activation of FX.

Conclusions:

  • The interactions between FIX/FX and TF, and the FIXa:FVIIIa interface, represent key regulatory points in coagulation.
  • Disrupting these specific molecular interactions offers a promising strategy for the development of targeted antithrombotic therapies.
  • Understanding these mechanisms can inform the design of new drugs to prevent or treat thrombotic disorders.